



[Dermatology](#)

**Cosentyx® (secukinumab)**

[Prescribing information](#)



Rheumatology

**Cosentyx® (secukinumab)**

[Prescribing information](#)



[Haematology](#)

**FABHALTA®▼ (iptacopan)**

[Prescribing information](#)



Haematology

**JAKAVI® (ruxolitinib)**

[Prescribing information](#)



Oncology

**KISQALI® (ribociclib)**

[Prescribing information](#)



Cardio-metabolic

**LEQVIO®▼ (inclisiran)**

[Prescribing information](#)



Haematology

**SCEMBLIX®▼ (asciminib)**

[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://prod.pro.novartis.com/uk-en/medicines>